Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the dierentiation/apoptosis induction therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ). Over the past 5 years, it has been well demonstrated that As 2 O 3 induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85*90%). The side eects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As 2 O 3 as post-remission therapy has given better survival than those treated with As 2 O 3 alone. The eect of As 2 O 3 has been shown to be related to the expression of APLspeci®c PML ± RARa oncoprotein, and there is a synergistic eect between As 2 O 3 and ATRA in an APL mouse model. Cell biology studies have revealed that As 2 O 3 exerts dose-dependent dual eects on APL cells. Apoptosis is evident when cells are treated with 0.5*2.0 mM of As 2 O 3 while partial dierentiation is observed using low concentrations (0.1*0.5 mM) of the drug. The apoptosis-inducing eect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell dierentiation induced by low dose arsenic remain to be explored. Interestingly, As 2 O 3 over a wide range of concentration (0.1*2.0 mM) induces degradation of a key leukemogenic protein, PML ± RARa, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers. Oncogene (2001) 20, 7146 ± 7153.
Introduction
Arsenic has long been known to act as a carcinogen, involved in human skin, lung, liver, kidney and urinary bladder cancers (Hu et al., 2000) . Paradoxically, arsenic has also long been demonstrated to have anticancer activity in some cases. In traditional Chinese medicine, arsenic trioxide (As 2 O 3 ) was recorded in the Compendium of Materia Medica by Mr Li Shi-Zhen (1518 ± 1593). In Western medicine, arsenous oxide (Fowler's solution) was used as a treatment of choice for chronic myeloid leukemia (CML) in the 19th century. As Osler stated in his 1892 textbook of medicine,`There are certain remedies that have an in¯uence upon the disease. Of these, arsenic, given in large doses, is the best. I have repeatedly seen improvement under its use.' However, due to toxic side eects of long-term heroic-dose of oral arsenic in most patients, and with the advent of modern radiotherapy and chemotherapy, the arsenic treatment for CML was given up in Western medicine (Kwong and Todd 1997; Tamm et al., 1998) .
Recently, a discovery on the therapeutic eect of As 2 O 3 in acute promyelocytic leukemia (APL) has revived this ancient drug Mervis, 1996; Look, 1998; Gallagher, 1998; Conrad, 1999; Warrell, 1999; Slack and Rusiniak, 2000; Wang and Chen, 2000; Chen et al., 2001) . APL is a special subtype of acute myeloid leukemia (AML), characterized by the speci®c chromosomal translocation t(15;17) with resultant leukemogenic PML ± RARa fusion gene, and the clinical response to dierentiation therapy using all-trans retinoic acid (ATRA) (Melnick and Licht, 2000) . Over the past several years, As 2 O 3 as an eective salvage treatment for relapsed and/or refractory APL patients has been con®rmed worldwide. Recently, this drug was formally approved by the State Drug Administration (SDA) in China (1999) and the Food and Drug Administration (FDA) of the United States of America (Cohen et al., 2001) . Encouraged by such a bedside discovery, mechanisms of action of As 2 O 3 have been actively addressed by many groups. The potentials of As 2 O 3 in the treatment of cancers other than APL are also under exploration. Here, we shall discuss the recent advances in the clinical practices and the mechanisms of action of As 2 O 3 in APL.
Clinical practice of As 2 O 3 in the treatment of APL

Clinical efficacy and pharmacokinetics
The recent clinical trial of As 2 O 3 was started in 1971. A group from the First Hospital aliated with the Harbin Medical University, China, used this compound through intravenous administration in more than 1000 cases of dierent types of cancer. Therapeutic eects were observed in several cancer types, including CML, lymphoma, esophageal cancer, and particularly APL. The preliminary result in APL was reported in 1992 (Sun et al., 1992) . A preparation containing arsenic with a trace amount of mercury chloride was administered at a dose of 10 mg As 2 O 3 /day and could induce clinical complete remission (CR) in 21 out of 32 (65.6%) patients without major toxic side eects. In 1996, two reports were made from China using puri®ed As 2 O 3 (0.16 mg/ kg/day). The Harbin group showed that As 2 O 3 treatment achieved CR in 52.4% (22/42) relapsed APL patients. The Shanghai Institute of Hematology (SIH) reported an even better result among 15 patients relapsed after ATRA and chemotherapy, with CR achieved in nine of 10 patients treated with As 2 O 3 alone and ®ve of ®ve patients treated with As 2 O 3 / chemotherapy combination. The treatment duration for induction of remission was 28 ± 54 days. Of note, the only non-responder in the SIH series had leukemic cells losing t(15;17) and PML ± RARa gene expression at relapse, although the disease was a typical APL at initial diagnosis, and the ®rst CR was induced by ATRA Shen et al., 1997) .
The pharmacokinetic studies were performed among eight relapsed patients by measuring plasma drug levels with gas chromatography. The results showed that after a peak level of 6.85 (5.54 ± 7.30) mmol/L, plasma arsenic was rapidly eliminated, with a t 1/2a of 0.89 (SD: 0.29) h and a t 1/2b of 12.13 (SD: 3.31) h. Hence, over most times during As 2 O 3 treatment, plasma arsenic levels¯uctuated between 0.1 ± 0.5 mM. Such a pharmacokinetic behavior did not alter after continuous use of As 2 O 3 . Increased amounts of arsenic appeared in the urine with a daily excretion accounting for approximately 1 ± 8% of the total daily dose used. Arsenic contents in hair and nails were increased during treatment and declined after withdrawal of the drug Shen et al., 1997) .
The Memorial Sloan-Kettering Cancer Center of New York was the ®rst to use As 2 O 3 in the treatment of APL patients in Western countries. In the ®rst report (Soignet et al., 1998) , eleven of the 12 patients had a CR after treatment with 0.06 ± 0.2 mg As 2 O 3 /kg/ day for 12 ± 39 days. A more recent U.S. multicenter study performed in 40 patients achieved a CR rate of 85% (Cohen et al., 2001) . In addition, the eectiveness of As 2 O 3 in the treatment of APL was also reported by some small-scale studies (Huang et al., 1998; Agis et al., 1999; Galimberti et al., 1999; Ohnishi et al., 2000; Zhang et al., 2000; Lin et al., 2000a) .
Recently, a trial using low dose As 2 O 3 (0.08 mg/kg/ day) was carried out in SIH ). Among 20 cases studied, a similar CR rate (80%) was achieved as compared to that attained with a conventional dose. Pharmacokinetic study was conducted in six patients given low dose As 2 O 3 . The mean C pmax was 2.63 (range, 1.54 ± 3.42) mmol/L, nearly half of the levels with a standard dose, and the ranges of t 1/2a and t 1/2b were 1.2 ± 2.7 h and 6.23 ± 14.9 h, respectively. Of note, the arsenic concentrations in the plasma of bone marrow (BM) in ®ve patients 24 h after administration of the drug at low dose were 0.061 ± 0.49 mmol/L.
Improvement of bleeding diathesis with As 2 O 3 treatment
Clinically, in patients with APL, the disease is frequently accompanied by a bleeding syndrome, which is often exacerbated by chemotherapy and causes death at the early stage of treatment. It was suggested that the aberrant expression of tissue factor (TF) in APL cells is at least one of the mechanisms underlying the pathogenesis of the APL coagulopathy (Barbui et al., 1998; Cheng et al., 1999; Tallman, 1999) . In APL patients receiving As 2 O 3 treatment, the improvement of disseminated intravascular coagulation (DIC) or hyper®brinolysis paralleled the amelioration of bleeding symptoms, the correction of plasma ®brinogen level, and the decrease in membrane procoagulant activity (PCA) as well as TF contents of APL blasts Agis et al., 1999) . Consistent with the in vivo ®ndings, the membrane PCA and TF at both protein and mRNA levels in APL cell line NB4 were rapidly down-regulated by 1 mM As 2 O 3 Ohsawa et al., 2000) .
Toxic side effects
During As 2 O 3 treatment in APL patients, there exists no BM depression. Instead, As 2 O 3 induces leukocytosis in about 50% of patients (Shen et al., 1997; Soignet et al., 1998 , Niu et al., 1999 Camacho et al., 2000) . These patients can even develop retinoic acid syndrome (RAS)-like symptoms such as fever, skin rash, edema, which were quickly relieved by steroid administration (Lin et al., 2000b) . The leukocytosis could resolve in all cases without chemotherapy (Camacho et al., 2000) . Other mild side eects were encountered in about 40 ± 50% of relapsed patients, such as fatigue, fever, edema, nausea, anorexia, diarrhea, emesis, headache, insomnia, cough, dyspnea, dermatitis, tachycardia, pain, hypokalemia, hypomagnesemia, and hyperglycemia. The most common (410%) Grade 3 or 4 adverse events were abdominal pain, epistaxis, dyspnea, hypoxia, bone pain, thrombocytopenia, neutropenia, hypokalemia, and hyperglycemia (Shen et al., 1997; Soignet et al., 1998; Cohen et al., 2001) . Of note, evident polyneuropathy compatible with chronic arsenic toxicity was noted in a few patients who received As 2 O 3 maintenance therapy and one even had marked distal muscular atrophy (Huang et al., 1998) . Cardiac dysrhythmias were reported with arsenic use . In a recent report from Japan, prolonged QT intervals were observed in all patients during induction therapy with As 2 O 3 and ventricular premature contractions were noticed during eight of 12 courses of therapy (Ohnishi et al., 2000) . QT prolongation was also seen in 16 (38%) patients in the study from FDA (Cohen et al., 2001) , which could return to baseline following cessation of As 2 O 3 .
In a recent clinical study conducted in SIH (Niu et al., 1999) , 11 newly diagnosed APL patients received As 2 O 3 treatment with informed consent. The CR was obtained in eight (72.7%) of them. However, As 2 O 3 treatment resulted in elevated plasma liver transaminase levels in seven cases and two died of severe hepatic toxicity, in contrast to the mild liver dysfunction in about one third of the patients treated for relapsed APL. It was thus recommended that ATRA should be used as the ®rst line drug for remission induction in newly diagnosed APL cases, while As 2 O 3 can be either included into multi-drug consolidation/ maintenance clinical trials after the ®rst CR or used as a rescue for relapsed cases.
Post-remission treatment among relapsed APL patients
In a report by SIH, 33 patients subject to distinct postremission treatment protocols after arsenic-induced CR were followed-up for 8 ± 48 months (Niu et al., 1999) . Three groups were formed, including four cases treated with chemotherapy alone (group A), 18 with As 2 O 3 alone (group B) and 11 with both As 2 O 3 and chemotherapy (group C). Although the estimated disease-free survival (DSF) rates at 1 and 2 years in all patients were 63.6% and 41.6%, respectively, recurrence of leukemia developed in 3/4 cases in group A, 12/18 in group B and 2/11 in group C. Combining chemotherapy and As 2 O 3 seems able to decrease the relapse and to yield a statistically signi®cant better survival status compared to arsenic alone as post-remission treatment (Niu et al., 1999) . Recent data showed that the estimated 2-year DFS (49.1%) was not dierent in the low dose As 2 O 3 treatment group as compared with that of the standard dose ).
Molecular remission
RT ± PCR analysis in both newly diagnosed and relapsed groups showed that application of As 2 O 3 for a short period of time was not sucient to eliminate minimal residual disease. Long-term use of the drug could, nevertheless, lead to a molecular remission at least in some patients (Niu et al., 1999) . Of ®ve patients reported by Zhang et al. (2000) , two achieved molecular remission (negative RT ± PCR for PML ± RARa fusion transcripts) by the end of the second and third cycles of As 2 O 3 therapy.
Dual activities of As 2 O 3 on APL cells in vivo and in vitro: induction of apoptosis and dierentiation
The clinical eectiveness of As 2 O 3 in APL has stimulated research activities aiming at an understanding of its mechanisms of action. Although many questions remain to be understood, in vivo and in vitro data suggested that induction of apoptosis and partial dierentiation of APL cells is likely to constitute the cellular basis of the eects of As 2 O 3 (Figure 1 ).
Evidences from APL patients
Initial clinical observations showed that during daily continuous intravenous infusion of As 2 O 3 in APL, a large amount of myelocyte-like cells and degenerative, dying cells with condensed nuclei losing cytoplasm appeared in both BM and peripheral blood, with the gradual reduction of leukemic promyelocytes. Interestingly, the myelocyte-like cells were derived from abnormal promyelocytes because they still carried the PML ± RARa gene as revealed by the¯uorescence in situ hybridization (FISH) analysis. Those degenerative cells were positively labeled by in situ terminal deoxynucleotidyl transferase, which is characteristic of programmed cell death . The presence of leukocytosis and RAS-like syndrome during arsenic treatment also supports the idea that As 2 O 3 could induce dierentiation. A similar ®nding was described by Huang et al. (1998) . Soignet et al. (1998) performed a further in vivo analysis on the mechanisms of action of As 2 O 3 . They reported that As 2 O 3 therapy induced a progressive decrease in the proportion of cells expressing CD33, an antigen associated with primitive myeloid cells, along with an increase in the proportion of cells expressing CD11b, an antigen restricted to mature myeloid elements. As 2 O 3 also induced the increment of cells that simultaneously expressed both antigens and displayed a hybrid signal of PML and RARa genes on FISH analysis. Interestingly, serial Western blot analysis of BM mononuclear cells during As 2 O 3 treatment showed induced expression of the precursor forms of caspase 2 and caspase 3 and activation of both caspase 1 and caspase 3.
Evidences from APL models and in vitro studies
Using syngenic grafts of leukemic blasts from PML ± RARa transgenic mice, Lallemand-Breitenbach et al. (1999) demonstrated that As 2 O 3 induced apoptosis and modest dierentiation of APL cells in vivo, and signi®cantly prolonged the survival of the diseased animals. In subcutaneous tumors which were formed by implantation of ATRA-resistant UF-1 APL cells into hGM-CSF-producing transgenic SCID mice (Kinjo et al., 2000) , tumor size was decreased to half the initial one after As 2 O 3 treatment, with the appearance of cells showing typical apoptotic morphology. Meanwhile, one of the As 2 O 3 -treated mice showed mature granulocytes in the diminished tumor.
In order to approach the complex mechanisms, in vitro eects of pharmacologic concentrations of As 2 O 3 on fresh APL cells and APL cell lines including ATRAsensitive NB4 cells, and ATRA-resistant NB4-derived sublines MR2, R1 and R2, were studied. The initial study showed that As 2 O 3 at 1.0 ± 2.0 mM could sig-ni®cantly induce apoptosis in APL cells regardless of their sensitivity to ATRA , which was widely con®rmed by other groups (Kitamura et al., 1997, and see later) . In order to establish an in vitro model of dierentiation, NB4 cells were treated with 0.1 ± 0.25 mM of As 2 O 3 over a long time of culture. Indeed, after 6 ± 9 days of treatment, cells started to present morphologic dierentiation with CD11b expression and dierentiation-associated cytochemical features. The dierentiation seems only a partial one since most cells were blocked at the myelocyte to metamyelocyte stage of maturation and no signi®cant increase of nitroblue-tetrazolium (NBT) reduction, a classical marker of granulocytic maturation, was observed in NB4 cells . Later, Gianni et al. (1998) isolated an As 2 O 3 -resistant NB4 subline (NB4-AsR). These cells failed to undergo apoptosis, but maintained the partial dierentiation response to arsenic. Of note, ATRA-triggered dierentiation and apoptosis were accelerated in As 2 O 3 -treated NB4-AsR cells.
Mechanisms of As 2 O 3 -induced apoptosis
A relatively wide spectrum of As 2 O 3 -induced apoptosis Several groups reported that HL-60 and U937 cell lines, both are of myeloid lineage, had weak responses to 1 mM As 2 O 3 in terms of growth and survival inhibition Kitamura et al., 1997; Zhang et al., 1998) , but a few groups observed that As 2 O 3 could induce apoptosis in these cells . Although dierent culture situations and/or variations of cell lines might be responsible for such a discrepancy (McCabe et al., 2000) , it may suggest that the cell type speci®city of As 2 O 3 -induced apoptosis is limited. Indeed, over the past few years, several studies found that As 2 O 3 could also inhibit cell growth and/or induce apoptosis among some lymphoma and solid tumor cell lines in a dose-dependent way. As 2 O 3 could also cause apoptosis in proliferating layers of human umbilical vein endothelial cells and prevent capillary tubule and branch formation under in vivo and in vitro assay conditions (Roboz et al., 2000) , raising the possibility of inhibiting metastasis. However, it should be noted that signi®cant induction of apoptosis in cell systems other than APL may sometimes require high concentration As 2 O 3 (5 ± 10 mM), a dose dicult to be achieved in vivo.
Mitochondria are involved in As 2 O 3 -induced apoptosis
The fact that As 2 O 3 induces apoptosis in a variety of cell types suggests that some common mechanisms should be involved. It is well established that mitochondria play a major rate-limiting role in apoptosis. Various pro-apoptotic signals converge on Figure 1 Working hypothesis for the mechanism of action of As 2 O 3 in remission induction of APL. As 2 O 3 induces remission of APL patients via two independent pathways: i.e., by triggering partial dierentiation and inducing apoptosis. High-dose As 2 O 3 -induced apoptosis involves mainly the -SH groups-related DCm collapse due to the opening of the PT pore, which leads to the release of pre-apoptotic factors from mitochondria to cytoplasma, followed by caspase activation and degradation of speci®c substrates. On the other hand, low-dose As 2 O 3 -induced dierentiation might be related to cyclic AMP pathway, nuclear receptor activity and/or regulation of histone acetylation. As 2 O 3 at both high-and low-dose triggers the degradation of PML ± RARa. PML ± RARa oncoprotein may therefore represent the common target for both ATRA and As 2 O 3 . However, the underlying mechanism seems to be dierent, the former targeting RARa through speci®c binding whereas the latter targeting PML moiety through SUMO-1-conjugation in a yet unknown manner. ?: Stimulation. ±|: Inhibition the mitochondria and trigger progressive disruption of mitochondrial transmembrane potentials (DCm) by modulating the permeability transition pore complex (PTPC), a multiprotein complex which interacts with the apoptosis-regulating protein Bcl-2/Bax family (Kroemer and de TheÂ , 1999; Costantini et al., 2000a) . As do most chemotherapeutic drugs, As 2 O 3 can also induce an early DCm collapse in intact APL cells (Cai et al., 2000) , maligant lymphocytes and carcinoma cell lines Seol et al., 2001) . As 2 O 3 -induced nuclear apoptosis also required mitochondria in an in vitro cell-free system, and As 2 O 3 acted on isolated mitochondria to induce PTPC opening and opened the puri®ed, reconstituted MPT in vitro in a cyclosporin A-and Bcl-2-inhibitable fashion (Larochette et al., 1999) . These data support that mitochondria, PTPC in particular, are important target of As 2 O 3 . Besides, in the APL model, glutathione (GSH)-reducing agent dithiothreitol (DTT) could eectively block As 2 O 3 -induced DCm collapse and apoptosis. In contrast, buthionine sulfoximine (BSO), a depleter of cellular GSH, and ascorbic acid substantially enhanced the eect of As 2 O 3 Dai et al., 1999; Jing et al., 1999; Cai et al., 2000) . BSO could also make As 2 O 3 -resistant HL60 and U937 cells to become sensitive to the compound. Therefore, it is presumed that As 2 O 3 -induced DCm collapse and apoptosis are associated with dithiol oxidation or cross-linking, which has been shown to be associated with a higher probability of PTPC opening (Figure 1, lower part) . Initially, we speculated that adenine nucleotide translocator (ANT) may be a target of As 2 O 3 (Cai et al., 2000) , since it is an important component of PTPC and contains the vicinal thiol group. In addition, ANT alone reconstituted into arti®cial lipid bilayers suces to confer a membrane permeabilization response to thiol crosslinking agents. However, a recent report showed that As 2 O 3 could not cause the oxidation of a critical cysteine residue (Cys 56 ) of puri®ed ANT (Costantini et al., 2000a) . In addition to the direct eects on PTPC, As 2 O 3 could disrupt mitochondria through some indirect mechanisms, such as the induction of reactive oxygen species (ROS). Nevertheless, there are controversies in literature with regard to the role of ROS. It was reported that the increased intracellular peroxide levels were accompanied by As 2 O 3 -induced apoptosis, which could be inhibited signi®cantly by N-Acetyl-Lcysteine (a thiol-containing antioxidant), diphenylene iodonium (an inhibitor of NADPH oxidase), 4,5-dihydro-1,3-benzene disulfonic acid (a selective scavenger of O 2 7 ) and catalase . However, other data showed that DTT blocked apoptosis induced by As 2 O 3 , but it could not antagonize As 2 O 3 -induced ROS production . In the experiments with butylated hydroxyanisole, Uslu et al. (2000) suggested that the apoptotic activity of As 2 O 3 in prostate and ovarian cancer cells was not through inducing superoxide generation.
Next to PTPC opening is the release of proapoptotic factors from mitochondria into the cytosol, where they activate sequentially upstream and downstream caspases such as caspase-9 (Costantini et al., 2000b; Brenner and Kroemer, 2000) . Indeed, As 2 O 3 could induce the release of cytochrome c from mitochondria to the cytosol Jing et al., 1999) . The activation of caspase-3 and cleavage of its speci®c substrates such as poly (ADP-ribose) polymerase (PARP) could also be seen in most cells treated with As 2 O 3 (Akao et al., 1999; Huang et al., 2000; Cai et al., 2000; Jing et al., 1999) (Figure 1, lower  part) . In addition to caspase-3, Kitamura et al. (2000a) showed that caspase 8 and Bid were also activated by As 2 O 3 in a GSH concentration-dependent manner in NB4 cells. An inhibitor of caspase 8 blocked not only the activation of caspase 3 but also the loss of DCm. However, Sternsdorf et al. (1999) realized that As 2 O 3 -induced apoptosis was caspase 3 independent and was only partially blocked by a global caspase inhibitor. In experiments conducted by SIH, caspase-3 was activated in 2 mM As 2 O 3 -treated Namalwa and Raji cells, but not in 1 mM of As 2 O 3 -treated BJAB, MOLT-4 and SKW-3 cells despite signi®cant apoptosis, indicating that caspase-3 was not always necessarily involved in As 2 O 3 -induced apoptosis .
Apart from the eect on mitochondria, as a pleiotropic agent, As 2 O 3 may have additional actions that also contribute to the induction of cell death, such as the activation of c-Jun NH 2 -terminal kinases and inactivation of the GTP binding site of monomeric tubulin (Li and Broom, 1999) . Although As 2 O 3 does not increase p53 level or activity in most cells, a marked increase in p53 protein level was seen during As 2 O 3 -induced apoptosis in a human gastric cancer cell line, while co-incubation with p53 anti-sense oligo-nucleotide suppressed both p53 over-expression and apoptosis induced by As 2 O 3 (Jiang et al., 2001) . Hence, mechanisms of action of As 2 O 3 may be very complex, depending on dose, cell type, or cellular environment (McCabe et al., 2000) .
Mechanisms of As 2 O 3 induced-dierentiation of APL
As previously mentioned, during the 0.08 ± 0.16 mg/kg/ day i.v. As 2 O 3 treatment, plasma As 2 O 3 levels were basically in the range of 0.1 ± 0.5 mM, corresponding to the concentrations inducing primarily dierentiation of APL cells in vitro Shen et al., 1997 Shen et al., , 2001 ). However, the mechanism underlying As 2 O 3 -induced dierentiation is still poorly understood. The fact that arsenic-resistant NB4-AsR subline failed to undergo apoptosis, but maintained the partial dierentiation response to As 2 O 3 suggested that distinct pathways may be responsible for the dierentiation and apoptosis (Gianni et al., 1998) . Recently, we showed that 0.1 mM As 2 O 3 did not induce dierentiation in ATRA-resistant APL cell lines. Furthermore, low-dose arsenic could induce partial dierentiation of ATRA-sensitive, but not ATRAresistant, HL-60 cells. In addition, the gene expression patterns modi®ed by low-dose As 2 O 3 overlapped with those by physiological concentrations of ATRA (Cai et al., 2000) . These data suggested a possible cross-talk between the retinoid signaling and the regulatory pathways modulated by As 2 O 3 (Figure 1, upper part) . Of note, in vivo studies proposed that As 2 O 3 and ATRA generate synergistic eect, such as an accelerated tumor regression and prolonged survival of animals (Lallemand-Breitenbach et al., 1999; Kinjo et al., 2000 , Rego et al., 2000 , although the bene®t of their combined use in cell culture is controversial , Gianni et al., 1998 Shao et al., 1998; Jing et al., 2001) . Nevertheless, As 2 O 3 showed no direct eect on RA receptors, in that the interaction of wildtype RARa and PML ± RARa with nuclear receptor co-repressor was not aected, and arsenic showed no obvious eect on the transactivation activity of RARa in an RARE-luciferase reporter system (Chen et al., 2001 and unpublished data) . Interestingly, as will be discussed below, the dierentiation of APL cells seems to be closely related to the modulation of PML ± RARa, the key protein in leukemogenesis.
Modulation of PML and PML ± RARa
The unique response of APL to As 2 O 3 implies the importance of intrinsic properties of APL cells. Interestingly, both wild-type PML and PML-RARa fusion protein have been shown to be major targets of arsenic treatment. PML is a tumor suppressor involved in complex functions including growth arrest and apoptosis induction. Normally PML is located in the nucleus on a speci®c subdomain named PML nuclear body (NB). In APL cells, due to the heterodimerization of PML ± RARa with wild-type PML, PML ± NBs are disrupted into nuclear microspeckle pattern, with loss of PML functions (Melnick and Licht, 2000, Andre et al., 1996) . A surprising ®nding was that 0.1 ± 2.0 mM of As 2 O 3 targets PML and PML ± RARa onto NBs, followed by degradation of these proteins Zhu et al., 1997; Sternsdorf et al., 1999; Gianni and de TheÂ , 1999) . Furthermore, As 2 O 3 increases covalent modi®cation of PML by SUMO-1, a small ubiquitin-like protein. The SUMO-1-polymodi®ed forms of PML are compartmentalized exclusively in the PML ± NBs in non-APL cells, while the unmodi®ed form of PML is found in the soluble nucleoplasmic fraction (Muller et al., 1998; Sternsdorf et al., 1999) . Therefore, As 2 O 3 -enhanced PML sumoylation constitutes the basis of the restoration and accumulation of the PML in enlarged NBs in As 2 O 3 -treated APL cells (for more information, please refer to the review article by Dr H de TheÂ in the same issue) (Figure 1 ).
There are controversies on the role of modulation of PML/PML ± RARa proteins in As 2 O 3 -induced apoptosis in APL cells. Through analysis of U937 cells stably expressing exogenous PML ± RARa gene, Sternsdorf et al. (1999) reported that As 2 O 3 could induce apoptosis only in U937 cells expressing the PML ± RARa but not in cells expressing PLZF ± RARa, a fusion gene generated as a result of the variant translocation t(11;17)(q23;q21) in APL. However, degradation of PML ± RARa and change of the PML-subcellular localization were similarly induced by As 2 O 3 in NB 4 cells and NB 4 -derived As 2 O 3 -resistant subline (Kitamura et al., 2000a) . Therefore, the contribution of PML ± RARa and PML modulation to apoptosis under the arsenic treatment seems to be relative even if present. In contrast, the degradation of PML ± RARa may play a crucial role in the dierentiation of APL cells, since this protein modulation can occur in the presence of very low concentration (0.1 ± 0.25 mM) of As 2 O 3 , while arsenic induced neither dierentiation of APL cells with t(11;17) nor degradation of PLZF ± RARa protein (Koken et al., 1999; Kitamura et al., 2000b) . The low-dose arsenic shows marked cell type selectivity, since it causes maturation of APL cells but exhibits little eect on other cancer cells, although a recent report suggested that low-dose As 2 O 3 can increase the lysis of myeloma cells by lymphokineactivated killer cells (Deaglio et al., 2001) . Importantly, there is also a marvelous target selectivity of As 2 O 3 , in that only the PML ± RARa, but not the wild-type RARa, is degraded. The relief of the transcriptional repression of PML ± RARa may pave the way for the operation of physiological RA signaling in granulocytic dierentiation, particularly at the stage of promyelocytes (Figure 1, upper part) . The possible synergistic eect of the arsenic with a number of important regulatory pathways such as RAR/RXR (Cai et al., 2000) , Cyclic AMP (Zhang JW, Zhu Q, Tong JH, unpublished data) and histone deacetylase inhibitor may also enhance the restoration of the cell dierentiation program.
